DGAP-News: Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
Retrieved on:
Tuesday, October 19, 2021
Biotechnology, Institute, Cancer, SCG, COVID-19, Ophthalmology, Marketing, ISIN, Hepatitis B, Helicobacter pylori, Virology, Institute of technology, Coronavirus, Severe acute respiratory syndrome coronavirus 2, WKN, CEO, Patient, Human papillomavirus infection, Conditional sentence, Infection, ACE2, Pharmaceutical industry, Vaccine, FYB207, SCG Cell Therapy Pte Ltd, FYB207, SCG CELL THERAPY PTE LTD
Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
Key Points:
- Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
- The APAC region is home to about 60% of the world's population and is the world's second largest healthcare market.
- SCG will be responsible for the development and manufacturing of FYB207 in Asia, and if approved, bring this innovative COVID-19 drug to patients and healthcare providers in the Asia-Pacific region."
- Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.